Regorafenib in Combination With Paclitaxel in Advanced Oesophagogastric Carcinoma
Status:
Completed
Trial end date:
2019-10-01
Target enrollment:
Participant gender:
Summary
Patients with advanced oesophagogastric cancer (OCG) have a very poor prognosis. After
progression on first line therapy, second line chemotherapy with paclitaxel and a VEGF-R2
targeting antibody has a proven benefit on survival. However, no data are available on the
combination of paclitaxel with kinase inhibitors in advanced OGC. Here the investigators
propose a Phase 1b study to assess the tolerability of regorafenib (an oral multi kinase
inhibitor) in combination with paclitaxel and to assess the uptake of paclitaxel in OCG
metastasis.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)